Aethlon Medical Inc. (AEMD)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Aethlon Medical, Inc. (AEMD) Q4 2026 Earnings Call Transcript
Aethlon Medical, Inc. (AEMD) Q4 2026 Earnings Call Transcript
Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript
Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript
Aethlon Medical, Inc. (AEMD) Q2 2026 Earnings Call Transcript
Aethlon Medical, Inc. ( AEMD ) Q2 2026 Earnings Call November 12, 2025 4:30 PM EST Company Participants James Frakes - CEO, CFO, Chief Accounting Officer, Secretary & Director Steven Larosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Investment Research, Inc. Jeremy Pearlman - Maxim Group LLC, Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and welcome to the Aethlon Medical Second Quarter Fiscal 2026 Earnings and Corporate Update Conference Call.
Aethlon Medical Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 8 | $18 | $16.16 | -$1.84 | -10.22% |
Aethlon Medical Inc. (AEMD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aethlon Medical Inc. ever had a stock split?
Aethlon Medical Inc. Profile
| Health Care Technology Industry | Healthcare Sector | James Frakes CEO | NASDAQ (CM) Exchange | 00808Y604 CUSIP |
| US Country | 14 Employees | - Last Dividend | 20 Oct 2025 Last Split | 2 Jan 2001 IPO Date |
Overview
Aethlon Medical, Inc. is a pioneering medical therapeutic company based in San Diego, California, with a vital focus on developing innovative products aimed at treating cancer and life-threatening infectious diseases. Established in 1999, Aethlon is at the forefront of advancing immunotherapeutic devices in the clinical stage, targeting the removal of tumor-derived exosomes and life-threatening viruses from the human circulatory system. This effort signifies a groundbreaking approach to addressing some of the most challenging medical conditions faced today in the United States.
Products and Services
- Aethlon Hemopurifier - A clinical-stage immunotherapeutic device developed by Aethlon Medical, Inc. This pioneering technology is designed to remove tumor-derived exosomes and life-threatening viruses from the human circulatory system. The Hemopurifier's mechanism stands on the cutting edge of medical science, offering a novel approach for the treatment of cancer and infectious diseases. By filtering these harmful entities directly from the blood, the Hemopurifier facilitates a unique method of therapy that could significantly impact patient outcomes in these critical areas of healthcare.
